

PSTP Interview Presentation

Robert Corty, PhD

UNC at Chapel Hill

October 31, 2019

Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping
2. Current project (5m): Gemcitabine and antibiotics
3. Future interests (1m): Computational Immunology

Table of Contents


1. PhD work (10m): Variance Heterogeneity in Genetic Mapping

- Genetic Mapping with SLM
- Genetic Mapping with DGLM
- New vQTL for anxiety-like behavior
- New mQTL for body weight
- New mQTL for circadian activity

2. Current project (5m): Gemcitabine and antibiotics

3. Future interests (1m): Computational Immunology

Main idea — Which of these is a QTL?



Main idea — Which of these is a QTL?




Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping
 - Genetic Mapping with SLM
 - Genetic Mapping with DGLM
 - New vQTL for anxiety-like behavior
 - New mQTL for body weight
 - New mQTL for circadian activity
2. Current project (5m): Gemcitabine and antibiotics
3. Future interests (1m): Computational Immunology


Introduction

QTL = “quantitative trait locus”


A genomic region containing factors that influence a quantitative trait of interest

- ① Measure the trait of interest in a population of genetically-diverse organisms
- ② Measure genetic variants at an appropriate density
- ③ Apply a statistical test to each locus to quantify the evidence that it is a QTL

Standard Linear Model (SLM)



Standard Linear Model (SLM)



Example Result with SLM




Table of Contents


1. PhD work (10m): Variance Heterogeneity in Genetic Mapping

- Genetic Mapping with SLM
- **Genetic Mapping with DGLM**
- New vQTL for anxiety-like behavior
- New mQTL for body weight
- New mQTL for circadian activity


2. Current project (5m): Gemcitabine and antibiotics

3. Future interests (1m): Computational Immunology


Double Generalized Linear Model (DGLM)



Double Generalized Linear Model (DGLM)



Double Generalized Linear Model (DGLM)



Double Generalized Linear Model (DGLM)




Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping
 - Genetic Mapping with SLM
 - Genetic Mapping with DGLM
 - New vQTL for anxiety-like behavior
 - New mQTL for body weight
 - New mQTL for circadian activity
2. Current project (5m): Gemcitabine and antibiotics
3. Future interests (1m): Computational Immunology

Original Study

Genes, Brain
and Behavior

Official publication of the International Behavioural and Neural Genetics Society

Genes, Brain and Behavior (2008) 7: 761–769


© 2008 The Authors

Journal compilation © 2008 Blackwell Publishing Ltd/*International Behavioural and Neural Genetics Society*


Identification of quantitative trait loci for locomotor activation and anxiety using closely related inbred strains

- Intercrossed C57BL/6J and C58/J, yielding 362 F2's.
- Measured six behavioral traits that model aspects of anxiety and exploratory behavior.
- Reported 7 QTL, but none for rearing behavior.

New vQTL



Understanding the vQTL



Understanding the vQTL (2)




Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping

- Genetic Mapping with SLM
- Genetic Mapping with DGLM
- New vQTL for anxiety-like behavior
- New mQTL for body weight**
- New mQTL for circadian activity

2. Current project (5m): Gemcitabine and antibiotics

3. Future interests (1m): Computational Immunology

Original Study

Genet. Res., Camb. (2000), **76**, pp. 27–40. With 2 figures. Printed in the United Kingdom © 2000 Cambridge University Press


27

Quantitative trait loci for directional but not fluctuating asymmetry of mandible characters in mice

- Backcrossed CAST/Ei into M16i
- 350 mice in mapping population, 92 markers
- Skull morphometrics, limb bone lengths, organ and body weight
- Published many QTL, but none for body weight


Leamy et al., *Genet. Res.*, 2000, *Physiol. Genom.*, 2002, Yi et al., *Genetics*, 2005

Body Weight at Three Weeks



Corty and Valdar, 2018

New mQTL



Corty and Valdar, 2018

Understanding the new QTL




Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping
 - Genetic Mapping with SLM
 - Genetic Mapping with DGLM
 - New vQTL for anxiety-like behavior
 - New mQTL for body weight
 - New mQTL for circadian activity
2. Current project (5m): Gemcitabine and antibiotics
3. Future interests (1m): Computational Immunology

Original Study



C57BL/6N Mutation in *Cytoplasmic FMRP interacting protein 2* Regulates Cocaine Response


- Intercrossed C57BL/6J and C56NL/6N, two “sister strains”
- Measured cocaine response and circadian behavior traits
- Reported 1 QTL for cocaine response, identified QTN
- No QTL for circadian behavior traits by standard analysis

New “mQTL”




Corty et al., 2018


Understanding the new QTL



Understanding the new QTL (2)




Domain-specific view of the Activity Trait



Corty et al., 2018

Main idea — Which of these is a QTL?



Main idea — Which of these is a QTL?




Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping
 - Genetic Mapping with SLM
 - Genetic Mapping with DGLM
 - New vQTL for anxiety-like behavior
 - New mQTL for body weight
 - New mQTL for circadian activity
2. Current project (5m): Gemcitabine and antibiotics
3. Future interests (1m): Computational Immunology


Idea

RESEARCH

CANCER

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Idea



Idea

ORIGINAL ARTICLE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

METHODS

We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate.

Results

Hazard Ratio of Antibiotic Exposure with Permanent Effect on Composite Adverse Events Grade 3+

any adverse event (217/533)

HR = 1.77, CI = (1.46, 2.14), p = 1.7e-09

hematologic (115/268)

HR = 1.64, CI = (1.26, 2.13), p = 2e-04

gastrointestinal (19/48)

HR = 2.14, CI = (1.12, 4.1), p = 0.019

constitutional (11/33)

HR = 1.33, CI = (0.61, 2.9), p = 0.46

hepatologic (6/21)

HR = 0.99, CI = (0.36, 2.71), p = 0.99

0.5

1.0

2.0

4.0

Significance

- ① suggests new considerations:
 - decrease dose of gem if on antibiotics
 - restraint in use of antibiotics
- ② requires further study
 - similar analysis on other datasets
 - randomized trial?
- ③ absolute joy to create, drive, and coordinate this project

Table of Contents

1. PhD work (10m): Variance Heterogeneity in Genetic Mapping
 - Genetic Mapping with SLM
 - Genetic Mapping with DGLM
 - New vQTL for anxiety-like behavior
 - New mQTL for body weight
 - New mQTL for circadian activity
2. Current project (5m): Gemcitabine and antibiotics
3. Future interests (1m): Computational Immunology

Exciting papers







RESOURCE

<https://doi.org/10.1038/s41590-019-0378-1>

nature
immunology

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry

Exciting papers

a**b****c****d****e****f**

Exciting technology

